These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M, Rachel Skinner S, Liu B, Cornall AM, Kaldor JM, Tabrizi SN. J Infect Dis; 2018 Apr 23; 217(10):1590-1600. PubMed ID: 29425358 [Abstract] [Full Text] [Related]
5. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection. Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T. J Infect Dis; 2019 Jan 09; 219(3):382-390. PubMed ID: 30299519 [Abstract] [Full Text] [Related]
8. Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease. Cameron RL, Palmer TJ, Cuschieri K, Kavanagh K, Roy K. Vaccine; 2024 Aug 30; 42(21):126177. PubMed ID: 39128198 [Abstract] [Full Text] [Related]
10. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Murillo R, Ordóñez-Reyes C. Int J Gynecol Cancer; 2019 Oct 30; 29(8):1317-1326. PubMed ID: 31455660 [Abstract] [Full Text] [Related]
14. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C. Lancet Public Health; 2016 Nov 30; 1(1):e8-e17. PubMed ID: 29253379 [Abstract] [Full Text] [Related]
15. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017. Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Regan DG, Hocking JS, Garland SM, Cornall AM, Atchison S, Bradshaw CS, McNulty A, Owen L, Marshall L, Russell DB, Kaldor JM, Chen MY. Vaccine; 2019 Oct 31; 37(46):6907-6914. PubMed ID: 31562001 [Abstract] [Full Text] [Related]
18. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, Serradell L, Burroni E, Confortini M, Mantellini P, Zappa M, Dominiak-Felden G. BMC Infect Dis; 2018 Jan 15; 18(1):38. PubMed ID: 29334901 [Abstract] [Full Text] [Related]
20. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Markowitz LE, Naleway AL, Lewis RM, Crane B, Querec TD, Weinmann S, Steinau M, Unger ER. Vaccine; 2019 Jun 27; 37(29):3918-3924. PubMed ID: 31160099 [Abstract] [Full Text] [Related] Page: [Next] [New Search]